相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients
Wei Wang et al.
ONCOTARGET (2017)
Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients
H. van Meir et al.
ONCOIMMUNOLOGY (2017)
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
Patricia Gaule et al.
JAMA ONCOLOGY (2017)
Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer
T. Donnem et al.
ANNALS OF ONCOLOGY (2016)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy
Panpan Zhang et al.
CANCER SCIENCE (2016)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Predictive relevance of PD-L1 expression combined with CD8+TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
Takaaki Tokito et al.
EUROPEAN JOURNAL OF CANCER (2016)
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer
Suresh Senan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform
Tzahi Neuman et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
Masaki Shimoji et al.
LUNG CANCER (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy
Zhong-Yi Dong et al.
TUMOR BIOLOGY (2016)
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers
Lauren Van der Kraak et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
Mari Mino-Kenudson
CANCER BIOLOGY & MEDICINE (2016)
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
Jin Sheng et al.
SCIENTIFIC REPORTS (2016)
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
Jin Peng et al.
CANCER RESEARCH (2015)
Stromal CD8+ T-cell Density-A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer
Tom Donnem et al.
CLINICAL CANCER RESEARCH (2015)
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline
Andrea Bezjak et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer
Megan E. Daly et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley et al.
LANCET ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer
Feifei Teng et al.
TRANSLATIONAL RESEARCH (2015)
Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non-Small Cell Lung Cancer
Therese Phillips et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2015)
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Hallie Wimberly et al.
CANCER IMMUNOLOGY RESEARCH (2015)
The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention
Joanna Domagala-Kulawik
TRANSLATIONAL LUNG CANCER RESEARCH (2015)
Radiation-Induced Modulation of Costimulatory and Coinhibitory T-Cell Signaling Molecules on Human Prostate Carcinoma Cells Promotes Productive Antitumor Immune Interactions
Michael B. Bernstein et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2014)
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi et al.
CANCER RESEARCH (2014)
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
Chad Tang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade
Janis M. Taube
ONCOIMMUNOLOGY (2014)
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
S. F. Slovin et al.
ANNALS OF ONCOLOGY (2013)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2013)
The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
Emily F. Stamell et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer
Encouse B. Golden et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer
Anne Auperin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer
Khalid I. Al-Shibli et al.
CLINICAL CANCER RESEARCH (2008)
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
Ping Zhang et al.
MOLECULAR IMMUNOLOGY (2008)
The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
Peter Goldstraw et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
分享论文
